EQT and KKR Explore Potential Takeover of Swiss Drugmaker PolyPeptide

Swiss contract drugmaker PolyPeptide Group AG is reportedly attracting takeover interest from major private equity firms EQT AB and KKR & Co. According to reports citing people familiar with the matter, the investment firms are in the early stages of evaluating a potential buyout of the company. PolyPeptide, which specializes in manufacturing peptide-based therapies, has become an attractive target within the pharmaceutical contract manufacturing sector. While discussions are ongoing, no final decision has been made, and there is no certainty that a formal offer will be extended. The news of private equity interest often signals a potential premium for shareholders, typically leading to upward pressure on the stock price. This development comes as private equity firms increasingly seek stable investment opportunities in the healthcare and life sciences industries.